Phase 3 trial of pancreatic cancer therapy misses primary endpoint

A phase 3 trial designed to assess an investigational drug for first-line treatment of metastatic pancreatic cancer failed to meet its primary endpoint of OS, according to the agent’s manufacturer.Development of the agent — pegvorhyaluronidase alfa (PEGPH20, Halozyme Therapeutics) — will be discontinued.Pegvorhyaluronidase alfa is the pegylated version of rHuPH20, Halozyme’s proprietary recombinant human hyaluronidase enzyme. rHuPH20 temporarily degrades hyaluronan, a naturally occurring glycosaminoglycan that can accumulate in the tumor microenvironment of certainRead More

Share on facebook
Share on twitter
Share on linkedin